Alphatec Holdings, Inc. (ATEC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Alphatec Holdings, Inc. is a medical technology company focused on spinal disorders, operating through subsidiaries Alphatec Spine, SafeOp Surgical, and EOS imaging. The company markets spinal implants and imaging equipment globally via independent sales agents and direct representatives.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $196.5 million | $150.7 million | $551.2 million | $434.8 million |
| Gross Profit | $137.3 million | $102.7 million | $382.4 million | $302.7 million |
| Gross Margin | 69.9% | 68.1% | 69.4% | 69.6% |
| Operating Loss | ($15.9 million) | ($33.7 million) | ($73.3 million) | ($112.4 million) |
| Net Loss | ($28.6 million) | ($39.6 million) | ($121.6 million) | ($128.8 million) |
| Diluted EPS | ($0.19) | ($0.28) | ($0.81) | ($0.90) |
| Cash & Equivalents | $155.7 million (as of Sept 30, 2025) | |||
| Total Debt (Principal) | $692.2 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 30% year-over-year in Q3 and 27% year-over-year for the nine months ended September 30, 2025. Growth was driven by increased product volume, expansion of the surgeon user base, and new product adoption.
- Operating Expenses: Total operating expenses rose 12% in Q3 and 10% YTD.
- Sales, General & Administrative (SG&A): Increased 14% in Q3 due to higher compensation costs and variable selling expenses tied to revenue growth.
- Litigation Expenses: Surged 212% in Q3 and 136% YTD, primarily due to a shareholder settlement in Q1 2025 and ongoing legal matters.
- R&D: Decreased 8% in Q3 and 6% YTD, largely due to reduced stock-based compensation.
- Debt Restructuring: In March 2025, the company issued $405.0 million in 0.75% Senior Convertible Notes due 2030. Proceeds were used to repurchase 80% of the 2026 Notes, resulting in a $17.6 million loss on debt extinguishment recorded in the first nine months of 2025.
- Interest Expense: Net interest expense increased 96% in Q3 and 86% YTD, driven by the new 2030 Notes and an additional draw on the Braidwell Term Loan.
Guidance, Outlook, and Risks
- Liquidity: The company reported $155.7 million in cash and cash equivalents. Management believes existing funds and access to financing are adequate for working capital and debt service needs.
- Debt Profile: As of September 30, 2025, outstanding debt includes $405.0 million in 2030 Notes, $63.3 million in 2026 Notes, $200.0 million in the Braidwell Term Loan, and $15.0 million in the Revolving Credit Facility.
- Risks:
- Trade Policy: New risk factor added regarding potential adverse effects from U.S. tariffs and trade restrictions on imported materials and international sales.
- Litigation: Ongoing legal proceedings remain unpredictable and could materially affect future results.
- Convertible Notes: The 2030 Notes include embedded conversion options and capped call transactions to limit dilution, which impact financial reporting and equity structure.
Key Facts for Investor Verification
- Debt Maturity Wall: Verify the repayment schedule for the remaining 20% of the 2026 Notes (maturing August 2026) and the company's plan to refinance or repay this obligation.
- Litigation Exposure: Review Note 8 for details on the specific shareholder settlement and the nature of ongoing litigation driving the 212% spike in legal expenses.
- Stock-Based Compensation: Monitor the $74.9 million of unrecognized compensation expense for RSUs and PRSUs, which will impact future operating expenses.
- Inventory Levels: Inventory decreased slightly to $166.9 million, but the company recorded an $11.3 million write-down for excess and obsolete inventory YTD; verify if this trend stabilizes.
- Convertible Note Conversion: Assess the likelihood of conversion for the 2030 Notes (conversion price ~$15.54) and the impact of the capped call transactions on potential dilution.